Dinaciclib as an effective pan-cyclin dependent kinase inhibitor in platinum resistant ovarian cancer.
Howard D, James D, Garcia-Parra J, Pan-Castillo B, Worthington J, Williams N, Coombes Z, Rees SC, Lutchman-Singh K, Francis LW, Rees P, Margarit L, Conlan RS, Gonzalez D.
Howard D, et al. Among authors: margarit l.
Front Oncol. 2022 Nov 25;12:1014280. doi: 10.3389/fonc.2022.1014280. eCollection 2022.
Front Oncol. 2022.
PMID: 36505806
Free PMC article.